Functional outcomes and complications following radiation therapy for prostate cancer: A critical analysis of the literature

European Urology

Volumn 61, Issue 1, 2012, Pages 112-127

  Budäus, Lars ^a   Bolla, Michel ^b   Bossi, Alberto ^c   Cozzarini, Cesare ^d   Crook, Juanita ^e   Widmark, Anders ^f   Wiegel, Thomas ^g  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Functional outcome; Intensity modulated radiotherapy; Prostate cancer; Radiation therapy; Tomotherapy

Indexed keywords

IODINE 125; PHOSPHODIESTERASE V INHIBITOR;

ABDOMINAL SURGERY; ACUTE TOXICITY; AGING; ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER RADIOTHERAPY; CHRONIC TOXICITY; COMORBIDITY; DIABETES MELLITUS; ENTERITIS; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HEMORRHOID; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MALE; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RECTUM HEMORRHAGE; REVIEW; RISK FACTOR; TOMOTHERAPY; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TUMOR VOLUME; URINE INCONTINENCE;

DOSE-RESPONSE RELATIONSHIP, RADIATION; EVIDENCE-BASED MEDICINE; HUMANS; MALE; PATIENT SELECTION; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 82255192463     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.09.027     Document Type: Review

References (133)

1. A. Heidenreich, G. Aus, and M. Bolla EAU guidelines on prostate cancer Eur Urol 53 2008 68 80 (Pubitemid 350166735)
2. M.R. Cooperberg, J.M. Broering, and P.R. Carroll Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28 2010 1117 1123
3. K.M. Kramer, C.L. Bennett, and A.S. Pickard Patient preferences in prostate cancer: a clinician's guide to understanding health utilities Clin Prostate Cancer 4 2005 15 23 (Pubitemid 41018178)
4. A.B. Jani, P.A. Johnstone, S.L. Liauw, V.A. Master, and P.J. Rossi Prostate cancer modality time trend analyses from 1973 to 2004: a Surveillance, Epidemiology, and End Results registry analysis Am J Clin Oncol 33 2010 168 172
5. C. Vargas, A. Martinez, and L.L. Kestin Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy Int J Radiat Oncol Biol Phys 62 2005 1297 1308 (Pubitemid 40982047)
6. L.W. Chan, P. Xia, and A.R. Gottschalk Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 72 2008 69 77
7. A. Jackson, M.W. Skwarchuk, and M.J. Zelefsky Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms Int J Radiat Oncol Biol Phys 49 2001 685 698 (Pubitemid 32112195)
8. S.T. Peeters, J.V. Lebesque, and W.D. Heemsbergen Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 64 2006 1151 1161
9. C. Fiorino, C. Cozzarini, and V. Vavassori Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions Radiother Oncol 64 2002 1 12 (Pubitemid 35223147)
10. C. Fiorino, G. Fellin, and T. Rancati Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study Int J Radiat Oncol Biol Phys 70 2008 1130 1137 (Pubitemid 351296107)
11. C. Fiorino, F. Alongi, and L. Perna Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer Int J Radiat Oncol Biol Phys 75 2009 29 35
12. G. Fellin, C. Fiorino, and T. Rancati Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study Radiother Oncol 93 2009 197 202
13. R. Valdagni, T. Rancati, and M. Ghilotti To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy Int J Radiat Oncol Biol Phys 74 2009 1431 1440
14. M.J. Zelefsky, S.A. Leibel, and P.B. Gaudin Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer Int J Radiat Oncol Biol Phys 41 1998 491 500 (Pubitemid 28275076)
15. A. Pollack, G.K. Zagars, and G. Starkschall Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105 (Pubitemid 34787842)
16. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial JAMA 294 2005 1233 1239 (Pubitemid 41352111)
17. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74 (Pubitemid 350251041)
18. B.S. Teh, W.Y. Mai, and B.M. Uhl Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis Int J Radiat Oncol Biol Phys 49 2001 705 712 (Pubitemid 32114105)
19. M.J. Zelefsky, E.J. Levin, and M. Hunt Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 70 2008 1124 1129 (Pubitemid 351296130)
20. A. Al-Mamgani, W.D. Heemsbergen, S.T. Peeters, and J.V. Lebesque Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer Int J Radiat Oncol Biol Phys 73 2009 685 691
21. O. Cahlon, M.J. Zelefsky, and A. Shippy Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes Int J Radiat Oncol Biol Phys 71 2008 330 337
22. G. De Meerleer, V. Fonteyne, and S. Meersschout Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy Radiother Oncol 89 2008 205 213
23. S. Arcangeli, B. Saracino, and M.G. Petrongari Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area Radiother Oncol 84 2007 148 155 (Pubitemid 47284530)
24. O. Matzinger, F. Duclos, and A. van den Bergh Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991 Eur J Cancer 45 2009 2825 2834
25. C. Cozzarini, C. Fiorino, and N. Di Muzio Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in patients with localized prostate cancer Radiother Oncol. 84 2007 164 170 (Pubitemid 47299141)
26. C. Cozzarini, C. Fiorino, and N. Di Muzio Hypofractionated adjuvant radiotherapy with helical tomotherapy after radical prostatectomy: planning data and toxicity results of a phase I-II study Radiother Oncol 88 2008 26 33
27. J.M. Michalski, H. Gay, A. Jackson, S.L. Tucker, and J.O. Deasy Radiation dose-volume effects in radiation-induced rectal injury Int J Radiat Oncol Biol Phys 76 Suppl 3 2010 S123 S129
28. D.J. Brenner Fractionation and late rectal toxicity Int J Radiat Oncol Biol Phys 60 2004 1013 1015 (Pubitemid 39440782)
29. A. Jackson, L.B. Marks, and S.M. Bentzen The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome Int J Radiat Oncol Biol Phys 76 Suppl 3 2010 S155 S160
30. Oxford Centre for Evidence-based Medicine Levels of Evidence. website: http://www.cebmnet/indexaspx?o=1025; accessed: July 13, 2011.
31. S.T. Peeters, W.D. Heemsbergen, and P.C. Koper Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996 (Pubitemid 46622106)
32. J. Phan, D.A. Swanson, L.B. Levy, R.J. Kudchadker, T.L. Bruno, and S.J. Frank Late rectal complications after prostate brachytherapy for localized prostate cancer: incidence and management Cancer 115 2009 1827 1839
33. S.T. Peeters, W.D. Heemsbergen, and W.L. van Putten Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy Int J Radiat Oncol Biol Phys 61 2005 1019 1034 (Pubitemid 40340897)
34. T. Akimoto, H. Muramatsu, and M. Takahashi Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding Int J Radiat Oncol Biol Phys 60 2004 1033 1039 (Pubitemid 39440786)
35. D.M. Herold, A.L. Hanlon, and G.E. Hanks Diabetes mellitus: a predictor for late radiation morbidity Int J Radiat Oncol Biol Phys 43 1999 475 479 (Pubitemid 29107163)
36. M.W. Skwarchuk, A. Jackson, and M.J. Zelefsky Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response Int J Radiat Oncol Biol Phys 47 2000 103 113 (Pubitemid 30179683)
37. V. Vavassori, C. Fiorino, and T. Rancati Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study Int J Radiat Oncol Biol Phys 67 2007 1401 1410 (Pubitemid 46467147)
38. R. Cheung, S.L. Tucker, and J.S. Ye Characterization of rectal normal tissue complication probability after high-dose external beam radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 58 2004 1513 1519 (Pubitemid 38438315)
39. E.H. Huang, A. Pollack, and L. Levy Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 54 2002 1314 1321 (Pubitemid 35380030)
40. C. Cozzarini, C. Fiorino, and G.L. Ceresoli Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy) Int J Radiat Oncol Biol Phys 55 2003 688 694 (Pubitemid 36170010)
41. C. Fiorino, G. Sanguineti, and C. Cozzarini Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer Int J Radiat Oncol Biol Phys 57 2003 953 962 (Pubitemid 37324112)
42. J.W. Denham, P.C. O'Brien, and R.H. Dunstan Is there more than one late radiation proctitis syndrome? Radiother Oncol 51 1999 43 53 (Pubitemid 29244090)
43. W.D. Heemsbergen, S.T. Peeters, P.C. Koper, M.S. Hoogeman, and J.V. Lebesque Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage Int J Radiat Oncol Biol Phys 66 2006 3 10 (Pubitemid 44175664)
44. M.J. Zelefsky, H. Chan, M. Hunt, Y. Yamada, A.M. Shippy, and H. Amols Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer J Urol 176 2006 1415 1419 (Pubitemid 44307191)
45. P.A. Kupelian, T.R. Willoughby, C.A. Reddy, E.A. Klein, and A. Mahadevan Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience Int J Radiat Oncol Biol Phys 68 2007 1424 1430 (Pubitemid 47176809)
46. S.A. Vora, W.W. Wong, S.E. Schild, G.A. Ezzell, and M.Y. Halyard Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 68 2007 1053 1058 (Pubitemid 47048576)
47. M.J. Zelefsky, T. Hollister, A. Raben, S. Matthews, and K.E. Wallner Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer Int J Radiat Oncol Biol Phys 47 2000 1261 1266 (Pubitemid 30421178)
48. D.Y. Gelblum, and L. Potters Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer Int J Radiat Oncol Biol Phys 48 2000 119 124 (Pubitemid 30488221)
49. K.M. Snyder, R.G. Stock, S.M. Hong, Y.C. Lo, and N.N. Stone Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis Int J Radiat Oncol Biol Phys 50 2001 335 341 (Pubitemid 32475740)
50. C. Fiorino, R. Valdagni, T. Rancati, and G. Sanguineti Dose-volume effects for normal tissues in external radiotherapy: pelvis Radiother Oncol 93 2009 153 167
51. N. Bittner, G.S. Merrick, K.E. Wallner, J.H. Lief, W.M. Butler, and R.W. Galbreath The impact of acute urinary morbidity on late urinary function after permanent prostate brachytherapy Brachytherapy 6 2007 258 266 (Pubitemid 350030635)
52. M.R. Cheung, S.L. Tucker, and L. Dong Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 67 2007 1059 1065
53. A. Harsolia, C. Vargas, and D. Yan Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study Int J Radiat Oncol Biol Phys 69 2007 1100 1109 (Pubitemid 47625853)
54. S.G. Williams, and A.L. Zietman Does radical treatment have a role in the management of low-risk prostate cancer? The place for brachytherapy and external beam radiotherapy World J Urol 26 2008 447 456
55. M.G. Sanda, R.L. Dunn, and J. Michalski Quality of life and satisfaction with outcome among prostate-cancer survivors N Engl J Med 358 2008 1250 1261 (Pubitemid 351439226)
56. S.G. Williams, J.L. Millar, G.M. Duchesne, M.J. Dally, P.L. Royce, and R.M. Snow Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy Radiother Oncol 73 2004 33 38 (Pubitemid 39304122)
57. M. Ferrer, J.F. Suarez, and F. Guedea Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 72 2008 421 432
58. J. Crook, H. Lukka, L. Klotz, N. Bestic, and M. Johnston Genitourinary Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer CMAJ 164 2001 975 981
59. J. Crook, N. Patil, and K. Wallace A phase III randomized trial of the timing of meloxicam with iodine-125 prostate brachytherapy Int J Radiat Oncol Biol Phys 77 2010 496 501
60. J. Crook, M. McLean, C. Catton, I. Yeung, J. Tsihlias, and M. Pintilie Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation Int J Radiat Oncol Biol Phys 52 2002 453 460 (Pubitemid 34170850)
61. D. Ash, D. Bottomley, B. Al-Qaisieh, B. Carey, K. Gould, and A. Henry A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer Radiother Oncol 84 2007 135 139 (Pubitemid 47284527)
62. G.S. Merrick, W.M. Butler, and K.E. Wallner Dysuria after permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 55 2003 979 985 (Pubitemid 36287000)
63. S. Gutman, G.S. Merrick, and W.M. Butler Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy BJU Int 97 2006 62 68
64. D. Bottomley, D. Ash, and B. Al-Qaisieh Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds Radiother Oncol 82 2007 46 49 (Pubitemid 46097133)
65. V. Kumar, H. Toussi, C. Marr, C. Hough, and P. Javle The benefits of radical prostatectomy beyond cancer control in symptomatic men with prostate cancer BJU Int 93 2004 507 509
66. D.Y. Gelblum, L. Potters, R. Ashley, R. Waldbaum, X.H. Wang, and S. Leibel Urinary morbidity following ultrasound-guided transperineal prostate seed implantation Int J Radiat Oncol Biol Phys 45 1999 59 67 (Pubitemid 29380075)
67. T. Ohashi, A. Yorozu, K. Toya, S. Saito, and T. Momma Serial changes of international prostate symptom score following I-125 prostate brachytherapy Int J Clin Oncol 11 2006 320 325 (Pubitemid 44306217)
68. M.D. Terk, R.G. Stock, and N.N. Stone Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate J Urol 160 1998 1379 1382 (Pubitemid 29480520)
69. M.A. Kollmeier, R.G. Stock, J. Cesaretti, and N.N. Stone Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy J Urol 173 2005 808 812 (Pubitemid 40239346)
70. N.J. Mabjeesh, J. Chen, A. Stenger, and H. Matzkin Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy Urology 70 2007 548 553 (Pubitemid 47464503)
71. C. Martens, G. Pond, D. Webster, M. McLean, C. Gillan, and J. Crook Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy Brachytherapy 5 2006 9 13
72. M.A. Elshaikh, J.C. Ulchaker, and C.A. Reddy Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study Int J Radiat Oncol Biol Phys 62 2005 164 169 (Pubitemid 40591938)
73. N.N. Stone, and R.G. Stock Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years Urology 69 2007 338 342 (Pubitemid 46274929)
74. C. Akbal, I. Tinay, F. Simsek, and L.N. Turkeri Erectile dysfunction following radiotherapy and brachytherapy for prostate cancer: pathophysiology, prevention and treatment Int Urol Nephrol 40 2008 355 363
75. M.W. Brown, J.P. Brooks, P.S. Albert, and M.M. Poggi An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinoma Prostate Cancer Prostatic Dis 10 2007 189 193 (Pubitemid 46881671)
76. C.A. Peters, R.G. Stock, and J.A. Cesaretti TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy Int J Radiat Oncol Biol Phys 70 2008 752 759 (Pubitemid 351199705)
77. M. Pinkawa, B. Gagel, and M.D. Piroth Erectile dysfunction after external beam radiotherapy for prostate cancer Eur Urol 55 2009 227 236
78. I. Goldstein, M.I. Feldman, P.J. Deckers, R.K. Babayan, and R.J. Krane Radiation-associated impotence. A clinical study of its mechanism JAMA 251 1984 903 910 (Pubitemid 14054895)
79. B. Mittal A study of penile circulation before and after radiation in patients with prostate cancer and its effect on impotence Int J Radiat Oncol Biol Phys 11 1985 1121 1125 (Pubitemid 15009569)
80. L. Perna, C. Fiorino, and C. Cozzarini Sparing the penile bulb in the radical irradiation of clinically localised prostate carcinoma: a comparison between MRI and CT prostatic apex definition in 3DCRT, Linac-IMRT and helical tomotherapy Radiother Oncol 93 2009 57 63
81. M. Roach, 3rd, J. Nam, G. Gagliardi, I. El Naqa, J.O. Deasy, and L.B. Marks Radiation dose-volume effects and the penile bulb Int J Radiat Oncol Biol Phys 76 Suppl 3 2010 S130 S134
82. G.J. van der Wielen, J.P. Mulhall, and L. Incrocci Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review Radiother Oncol 84 2007 107 113 (Pubitemid 47284535)
83. G.J. van der Wielen, W.L. van Putten, and L. Incrocci Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial Int J Radiat Oncol Biol Phys 68 2007 479 484 (Pubitemid 46694167)
84. W.M. Mendenhall, R.H. Henderson, D.J. Indelicato, S.R. Keole, and N.P. Mendenhall Erectile dysfunction after radiotherapy for prostate cancer Am J Clin Oncol 32 2009 443 447
85. C. Gillan, A. Kirilova, A. Landon, I. Yeung, G. Pond, and J. Crook Radiation dose to the internal pudendal arteries from permanent-seed prostate brachytherapy as determined by time-of-flight MR angiography Int J Radiat Oncol Biol Phys 65 2006 688 693 (Pubitemid 43795815)
86. P.W. McLaughlin, V. Narayana, and A. Meirovitz Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI Int J Radiat Oncol Biol Phys 61 2005 20 31 (Pubitemid 40039101)
87. A. Sethi, N. Mohideen, L. Leybovich, and J. Mulhall Role of IMRT in reducing penile doses in dose escalation for prostate cancer Int J Radiat Oncol Biol Phys 55 2003 970 978 (Pubitemid 36286999)
88. J. Kao, J. Turian, and A. Meyers Sparing of the penile bulb and proximal penile structures with intensity-modulated radiation therapy for prostate cancer Br J Radiol 77 2004 129 136 (Pubitemid 38313226)
89. M.K. Buyyounouski, E.M. Horwitz, R.A. Price, A.L. Hanlon, R.G. Uzzo, and A. Pollack Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment Int J Radiat Oncol Biol Phys 58 2004 743 749 (Pubitemid 38221130)
90. S.L. Turner, K. Adams, C.A. Bull, and M.P. Berry Sexual dysfunction after radical radiation therapy for prostate cancer: a prospective evaluation Urology 54 1999 124 129 (Pubitemid 29323344)
91. C.B. Johannes, A.B. Araujo, H.A. Feldman, C.A. Derby, K.P. Kleinman, and J.B. McKinlay Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study J Urol 163 2000 460 463 (Pubitemid 30060493)
92. G. Salomon, H. Isbarn, and L. Budaeus Importance of baseline potency rate assessment of men diagnosed with clinically localized prostate cancer prior to radical prostatectomy J Sex Med 6 2009 498 504
93. T.M. Zagar, R.G. Stock, J.A. Cesaretti, and N.N. Stone Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS Brachytherapy 6 2007 26 33 (Pubitemid 46187327)
94. A.L. Burnett, G. Aus, and E.D. Canby-Hagino Erectile function outcome reporting after clinically localized prostate cancer treatment J Urol 178 2007 597 601 (Pubitemid 47030514)
95. A.G. Macdonald, M. Keyes, A. Kruk, G. Duncan, V. Moravan, and W.J. Morris Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: is dose to the penile bulb important? Int J Radiat Oncol Biol Phys 63 2005 155 163 (Pubitemid 41583554)
96. P. Fransson, and A. Widmark Does one have a sexual life 15 years after external beam radiotherapy for prostate cancer? Prospective patient-reported outcome of sexual function comparison with age-matched controls Urol Oncol 29 2011 137 144
97. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
98. A. Widmark, O. Klepp, and A. Solberg Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial Lancet 373 2009 301 308
99. L. Incrocci Sexual function after external-beam radiotherapy for prostate cancer: what do we know? Crit Rev Oncol Hematol 57 2006 165 173 (Pubitemid 43139701)
100. L. Incrocci, W.C. Hop, and A.K. Slob Efficacy of sildenafil in an open-label study as a continuation of a double-blind study in the treatment of erectile dysfunction after radiotherapy for prostate cancer Urology 62 2003 116 120 (Pubitemid 36802083)
101. J.D. Schiff, N. Bar-Chama, J. Cesaretti, and R. Stock Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function BJU Int 98 2006 1255 1258 (Pubitemid 44721237)
102. S.A. Mangar, M.R. Sydes, and H.L. Tucker Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397) Radiother Oncol 80 2006 355 362 (Pubitemid 44419432)
103. S. Lehrer, J. Cesaretti, N.N. Stone, and R.G. Stock Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation BJU Int 98 2006 979 981 (Pubitemid 44536443)
104. J.A. Cesaretti, J. Kao, N.N. Stone, and R.G. Stock Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at > or = 7 years of follow-up BJU Int 100 2007 362 367 (Pubitemid 47036592)
105. A. Gomez-Iturriaga Pina, J. Crook, J. Borg, G. Lockwood, and N. Fleshner Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged < or = 55 years with favorable prostate cancer Urology 75 2010 1412 1416
106. N. Mabjeesh, J. Chen, A. Beri, A. Stenger, and H. Matzkin Sexual function after permanent 125I-brachytherapy for prostate cancer Int J Impot Res 17 2005 96 101 (Pubitemid 40300001)
107. I.M. Thompson, C.M. Tangen, and E.A. Klein Is there a standard of care for pathologic stage T3 prostate cancer? J Clin Oncol 27 2009 2898 2899
108. M. Bolla, H. van Poppel, and L. Collette Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) Lancet 366 2005 572 578 (Pubitemid 41140332)
109. C.M. Moinpour, K.A. Hayden, and J.M. Unger Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy J Clin Oncol 26 2008 112 120
110. T. Wiegel, D. Bottke, and U. Steiner Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 2009 2924 2930
111. D. Bottke, T.M. de Reijke, D. Bartkowiak, and T. Wiegel Salvage radiotherapy in patients with persisting/rising PSA after radical prostatectomy for prostate cancer Eur J Cancer 45 Suppl 1 2009 148 157
112. T. Wiegel, G. Lohm, and D. Bottke Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome - results of a retrospective study Int J Radiat Oncol Biol Phys 73 2009 1009 1016
113. A.J. Stephenson, P.T. Scardino, and M.W. Kattan Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy J Clin Oncol 25 2007 2035 2041 (Pubitemid 46972788)
114. T. Do, R.G. Parker, C. Do, L. Tran, L. Do, and D. Dolkar Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy Cancer J Sci Am 4 1998 324 330
115. J.B. Madalinska, M.L. Essink-Bot, H.J. de Koning, W.J. Kirkels, P.J. van der Maas, and F.H. Schroder Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer J Clin Oncol 19 2001 1619 1628 (Pubitemid 32230861)
116. R.R. Rajendran, J.P. Plastaras, R. Mick, D. McMichael Kohler, A. Kassaee, and N. Vapiwala Daily isocenter correction with electromagnetic-based localization improves target coverage and rectal sparing during prostate radiotherapy Int J Radiat Oncol Biol Phys 76 2010 1092 1099
117. D. Wolff, F. Stieler, and B. Hermann Clinical implementation of volumetric intensity-modulated arc therapy (VMAT) with ERGO++ Strahlenther Onkol 186 2010 280 288
118. N. Bittner, W.M. Butler, and J.L. Reed Electromagnetic tracking of intrafraction prostate displacement in patients externally immobilized in the prone position Int J Radiat Oncol Biol Phys 77 2010 490 495
119. C.R. King, J.D. Brooks, H. Gill, T. Pawlicki, C. Cotrutz, and J.C. Presti Jr. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial Int J Radiat Oncol Biol Phys 73 2009 1043 1048
120. J.A. Talcott, C. Rossi, and W.U. Shipley Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer JAMA 303 2010 1046 1053
121. O. Matzinger, P. Poortmans, and J.Y. Giraud Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review Radiother Oncol 90 2009 285 290
122. C. Jeldres, N. Suardi, and F. Saad High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer Eur Urol 54 2008 97 106 (Pubitemid 351713677)
123. L.B. Marks, R.K. Ten Haken, and M.K. Martel Guest editor's introduction
124. T.J. Wilt, R. MacDonald, I. Rutks, T.A. Shamliyan, B.C. Taylor, and R.L. Kane Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer Ann Intern Med 148 2008 435 448 (Pubitemid 351665443)
125. D.P. Dearnaley, M.R. Sydes, R.E. Langley, J.D. Graham, R.A. Huddart, and I. Syndikus The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397) Radiother Oncol 83 2007 31 41 (Pubitemid 46527948)
126. G.A. Viani, E.J. Stefano, and S.L. Afonso Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials Int J Radiat Oncol Biol Phys 74 2009 1405 1418
127. A. Zapatero, F. Valcarcel, F.A. Calvo, R. Algas, A. Bejar, and J. Maldonado Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study J Clin Oncol 23 2005 6561 6568 (Pubitemid 46190249)
128. H. Ishiyama, M. Kitano, T. Satoh, S. Kotani, M. Uemae, and K. Matsumoto Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity Int J Radiat Oncol Biol Phys 75 2009 23 28
129. W.R. Lee, K. Bae, C. Lawton, M. Gillin, G. Morton, and S. Firat Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019 Cancer 109 2007 1506 1512 (Pubitemid 46595685)
130. R.F. Sanchez-Ortiz, G.A. Broderick, E.S. Rovner, A.J. Wein, R. Whittington, and S.B. Malkowicz Erectile function and quality of life after interstitial radiation therapy for prostate cancer Int J Impot Res 12 Suppl 3 2000 S18 S24 (Pubitemid 32049654)
131. G.S. Merrick, W.M. Butler, R.W. Galbreath, R.L. Stipetich, L.J. Abel, and J.H. Lief Erectile function after permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 52 2002 893 902 (Pubitemid 34223438)
132. G.S. Merrick, K. Wallner, W.M. Butler, J.H. Lief, and S. Sutlief Short-term sexual function after prostate brachytherapy Int J Cancer 96 2001 313 319 (Pubitemid 32946477)
133. A.V. Taira, G.S. Merrick, R.W. Galbreath, W.M. Butler, K.E. Wallner, and B.S. Kurko Erectile function durability following permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 75 2009 639 648